Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 May 19;19(1):32.
doi: 10.1186/s12959-021-00284-9.

Prevalence and risk factors of thrombotic events on patients with COVID-19: a systematic review and meta-analysis

Xiaoming Xiong #  1   2   3 , Jianhua Chi #  1   2   3 , Qinglei Gao  4   5   6
Affiliations

Prevalence and risk factors of thrombotic events on patients with COVID-19: a systematic review and meta-analysis

Xiaoming Xiong et al. Thromb J. .

Abstract

Background: Coagulation abnormalities in COVID-19 patients accompanied with poor prognosis. This study aimed to determine the prevalence and risk factors of thrombotic events on COVID-19 patients.

Methods: We systematically reviewed all the studies about thrombotic events on COVID-19 patients in PubMed, Embase, Web of Science, MedRxiv, bioRxiv, from Dec 1, 2019 to July 5, 2020. The weighted mean difference (MD) or odds ratio (OR) or relative risk (RR) with 95 % confidence intervals (CI) for clinical data in COVID-19 patients with or without thrombotic events was calculated.

Results: 12 articles contained 1083 patients were included for meta-analysis. The prevalence of thrombosis was 22 % (95 % CI 0.08-0.40) in COVID-19 patients and increased to 43 % (95 % CI 0.29-0.65) after admission to the intensive care unit (ICU). Compared with non-thrombotic patients, thrombotic patients had higher levels of D-dimer (MD = 2.79 μg/ml, 95 % CI 2.27-3.31 μg/ml), lactate dehydrogenase (LDH) (MD = 112.71 U/L, 95 % CI 62.40-163.02 U/L), and white blood cells (WBC) (MD = 1.14 *109/L, 95 % CI 0.47-1.81*109/L) while decreased lymphocytes (MD= -0.20*109/L, 95 % CI -0.38 - -0.02*109/L). Age, platelet counts, and male sex tended to be risks while diabetes tended to be a protection for thrombosis for COVID-19 patients, although no statistical difference was achieved. Finally, patients with thrombosis were at a higher risk of death (OR = 2.39, 95 % CI 1.36-4.20).

Conclusions: Prevalence of thrombosis in COVID-19 patients was high, especially in ICU, though pharmacologic thromboembolism prophylaxis was applied. Therefore, higher levels of D-dimer, LDH, WBC, and decreased lymphocytes needed to be paid close attention to in patients with COVID-19.

Keywords: Anticoagulants; COVID-19; Prevalence; Risk factors; Thrombosis.

PubMed Disclaimer

Conflict of interest statement

The authors declare that they have no competing interests.

Figures

Fig. 1
Fig. 1
PRISMA flowchart of included studies
Fig. 2
Fig. 2
Prevalence of thrombosis in patients with COVID-19. a, Overall prevalence of thrombosis in hospitalized patients with COVID-19. b, Prevalence of thrombosis in patients with COVID-19 in ICU
Fig. 3
Fig. 3
Risk factors analysis of thrombotic events for COVID-19 patients Thrombotic risk of D-dimer (a), LDH (b), WBC (c), lymphocytes (d), age (e), platelets count (f), gender (g), BMI (h), hypertension (i), coronary artery disease (j), current-smoking (k), malignancy (l), CRP (m), hemoglobin (n), fibrinogen (o), and diabetes (p) for COVID-19 patients. q, The risk of motality for COVID-19 patients with thrombotic events. Note: Heterogeneity is defined according to the I2 index calculated. Random or fixed effect models were used base on the heterogeneity
See this image and copyright information in PMC

References

    1. Hossain MP, Junus A, Zhu X, Jia P, Wen TH, Pfeiffer D, et al. The effects of border control and quarantine measures on the spread of COVID-19. Epidemics. 2020;32:100397. doi: 10.1016/j.epidem.2020.100397. - DOI - PMC - PubMed
    1. Coronavirus Outbreak. Available from: https://www.worldometers.info/coronavirus/.
    1. Levi M, Thachil J, Iba T, Levy JH. Coagulation abnormalities and thrombosis in patients with COVID-19. The Lancet Haematology. 2020;7(6):e438-e40. doi: 10.1016/S2352-3026(20)30145-9. - DOI - PMC - PubMed
    1. Chen L, Yu J, He W, Chen L, Yuan G, Dong F, et al. Risk factors for death in 1859 subjects with COVID-19. Leukemia. 2020:1–11. - PMC - PubMed
    1. Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020;395(10223):497–506. doi: 10.1016/S0140-6736(20)30183-5. - DOI - PMC - PubMed